May 21, 2009 — In patients with follicular lymphoma, rituximab (Rituxan, Genentech; MabThera, Roche) maintenance therapy significantly improves overall survival, compared with observation or ...

New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations ...

low tumor burden follicular lymphoma can substantially delay the need for further treatment. At nearly 15 years of follow-up, 65% of those assigned to rituximab maintenance and 48% of those given ...

"As when initially reported, the totality of these data continue to support a retreatment strategy rather than maintenance rituximab when treating low tumor burden follicular lymphoma with ...

February 18, 2009 — Rituximab should be used for maintenance therapy in patients with relapsed or refractory follicular lymphoma after successful induction therapy because it significantly ...

Rituximab plus chemotherapy has ... and not every patient will undergo maintenance therapy after induction for follicular lymphoma. An OS benefit did not occur; however, this might be an elusive ...

in patients with previously untreated follicular lymphoma. Both regimens were followed by rituximab maintenance therapy. Follow-up continued to 120 weeks. The researchers found that the rate of ...